Left ventricular assist devices in heart failure

Ahmet Kilic, Gorav Ailawadi

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


End-stage heart failure is an ever-growing and devastating disease. The median survival for patients with heart failure on ionotropic support alone is a meager 6 months. Historically, the only option for these patients was to be listed for heart transplantation. Out of medical necessity, the idea of left ventricular assist device (LVAD) as a bridge to transplantation was born. Since their approval by the US FDA, LVADs have quadrupled the survival in patients with heart failure. The increase in survival has also been accompanied by decreased perioperative morbidity, better biocompatibility and longer device life over first-generation LVADs. Undoubtedly, LVADs have changed the landscape of heart failure treatment and will continue to do so in the foreseeable future. In this review, we will highlight the landmark studies that have established LVADs as a therapeutic option for heart failure, as well as reviewing the current LVADs available and speculating on the advancements that will be made in the upcoming years.

Original languageEnglish (US)
Pages (from-to)649-656
Number of pages8
JournalExpert review of cardiovascular therapy
Issue number5
StatePublished - May 1 2012
Externally publishedYes


  • bridge to transplant
  • destination therapy
  • heart failure
  • mechanical circulatory support
  • ventricular assist device

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Left ventricular assist devices in heart failure'. Together they form a unique fingerprint.

Cite this